Two Lidoderm Class Action Deals Worth $271M Get Final OK
A California federal judge on Wednesday approved "excellent" settlements ending claims that Teikoku, Endo and Actavis violated antitrust laws by stalling the release of a generic form of the Lidoderm pain...To view the full article, register now.
Already a subscriber? Click here to view full article